Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Criteria

Inclusion Criteria:

• The investigators concluded that the participants continued to benefit from treatment with Jaktinib.

• The participants have been fully informed and voluntarily signed informed consent.

• The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance.

• The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks.

Exclusion Criteria:

• There were any grade ≥3 adverse events within 4 weeks prior to enrollment and no return to grade 1 or normal.

• Within 4 weeks prior to enrollment, participants had the following infectious diseases: tuberculosis infection requiring treatment; HIV-positive, syphilis, HBV infection, HCV infection.

• The investigators considered participants unsuitable for this study.